Indication
Epstein-Barr Virus Related Carcinoma
2 clinical trials
4 products
Product
NanatinostatProduct
ValganciclovirProduct
PembrolizumabClinical trial
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative StudiesStatus: Recruiting, Estimated PCD: 2025-02-01
Product
VK-2019